HAYA Therapeutics
Programmable Therapeutics for Causal Biology - Science Guides Us. The Genome Powers Us. Patients Ground Us.
68 employees · est. 2019 · Switzerland
RiboNova, Inc.
Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also have tRNA discovery.
7 employees · est. 2011 · Wynnewood, United States
RiboNova, Inc. is the older company (2019 vs 2011); HAYA Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | HAYA Therapeutics | RiboNova, Inc. |
|---|---|---|
| Founded | ||
| Founded | 2019 | 2011 older |
| Headquarters | ||
| Headquarters | Switzerland | Wynnewood, United States |
| Employees | ||
| Employees | 68 larger | 7 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Undisclosed | Series Unknown |
| Total Funding | ||
| Total Funding | $1.02B | $25.00K |
| Funding Rounds | ||
| Funding Rounds | 9 | 2 |
| Services | ||
| Services | Development of precise RNA therapies for reprogramming disease driving cell-states | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients suffering from rare and chronic diseases | Not tracked yet |
| Taxonomy | ||
| Taxonomy | RNA-based Therapeutics, Precision Medicine, Cardiovascular Disease Treatment, Cancer Treatment, Long Non-coding RNAs (lncRNAs), Cell-specific Therapeutics, Biopharmaceutical Therapy, Genomic Medicines, Fibrosis Treatment, Disease-modifying Therapeutics | Biopharmaceutical Company, Rare Diseases, Mitochondrial Disease, Treatment, Drug Discovery, Precision Medicine, TRNA, Genetic Diagnosis, DNA Sequencing, Ribonucleic Acid, Clinical Biomarkers, Therapeutic Targets, Translational Medicine, Phase-2 Ready Drug |
| Website | ||
| Website | hayatx.com | ribonova.com |
About HAYA Therapeutics
HAYA Therapeutics is a precision medicines company focused on developing RNA-guided programmable therapeutics targeting the regulatory genome to address serious health conditions such as cardiovascular disease and cancer. The company's innovative cell-state modifying platform provides novel insights...
About RiboNova, Inc.
RiboNova, Inc. is a biopharmaceutical company founded in 2011, with a primary focus on developing treatments for mitochondrial disease and other serious rare diseases. The company's flagship asset, R007, is a Phase-2 ready small molecule drug designed to address all forms of genetically-confirmed mi...
We will tell you when either one moves
BounceWatch watches HAYA Therapeutics and RiboNova, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at HAYA Therapeutics and RiboNova, Inc. — by email.
Frequently Asked Questions
Compare HAYA Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at HAYA Therapeutics on 9 Jun 2026, and RiboNova, Inc. on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
